Bock Rebecca, Babayeva Mariana, Loewy Zvi G
Stern College for Women, Yeshiva University, New York, NY, USA.
Touro College of Pharmacy, New York, NY, USA.
Methods Mol Biol. 2022;2547:187-199. doi: 10.1007/978-1-0716-2573-6_8.
The SARS-CoV-2 virus has been the subject of intense pharmacological research. Various pharmacotherapeutic approaches including antiviral and immunotherapy are being explored. A pandemic, however, cannot depend on the development of new drugs; the time required for conventional drug discovery and development is far too lengthy. As such, repurposing drugs is being used as a viable approach for identifying pharmacological agents for COVID-19 infections. Evaluation of repurposed drug candidates with pharmacogenomic analysis is being used to identify near-term pharmacological remedies for COVID-19.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒一直是深入药理学研究的对象。目前正在探索包括抗病毒和免疫疗法在内的各种药物治疗方法。然而，一场大流行不能仅仅依赖于新药的研发；传统药物发现和开发所需的时间太长了。因此，药物重新利用正被用作一种可行的方法来确定用于治疗2019冠状病毒病（COVID-19）感染的药物。利用药物基因组学分析对重新利用的候选药物进行评估，以确定针对COVID-19的近期药物治疗方法。
